PGNYNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31

Progyny, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$27.84+0.98 (+3.65%)

Close on Oct 19, 2026

Market cap: $2.29B
P/E (TTM): 30.3
Dividend yield: –

Dividends

Progyny has not reported a dividend

No dividend per share appears in Progyny's annual filings since fiscal 2017.

Where these numbers come from

Parsed from the XBRL in Progyny's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PGNY.

Revenue growth5.5% · median 8.1%

Gross margin24.6% · median 55.0%

Operating margin8.6% · median 11.4%

Net margin6.0% · median 6.0%

Company	Revenue	Growth
DVA	$14.01B	+6.4%
AGL	$5.92B	+0.3%
CON	$2.29B	+14.0%
PGNY	$1.31B	+5.5%
SHC	$1.22B	+8.1%
VMD	$301.61M	+25.2%

Company

Next earnings (est.): Nov 5, 2026, after close
Exchange: Nasdaq
Industry: Services-Misc Health & Allied Services, NEC
Fiscal year ends: December 31
Employees: 856
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 1551306

Advertisement
300 × 250